Department of Cardiovascular Medicine, Heart, Vascular, and Thoracic Institute, Cleveland Clinic, 9500 Euclid Avenue, Desk J3-4, Cleveland, OH, 44195, USA.
Curr Cardiol Rep. 2020 Sep 10;22(11):143. doi: 10.1007/s11886-020-01384-0.
This review aims to summarize our current understanding and management strategies of acute cardiorenal syndrome (CRS).
The definition of acute CRS remains debated, in part due to the lack of reliable insights into salt and water handling of the kidneys beyond impairment in glomerular filtration. Protocolized use of loop diuretics to ensure adequate delivery to their target of action, as well as segmental tubular blockade with adjunctive use of thiazide diuretics, acetazolamide, amiloride, or sodium-glucose transporter 2 (SGLT2) inhibitors, may result in more effective natriuresis in patients with acute CRS who exhibit diuretic resistance. Other strategies, such as modulating renal sodium avidity with the use of hypertonic saline, reduction of intra-abdominal pressure, or device-based salt and volume removal, are promising and warrant further investigation. Acute CRS remains a significant contributor of morbidity and mortality for the acute heart failure population. New strategies have challenged current dogmas in our understanding of its pathophysiology, which may lead to potential new treatment approaches.
本文旨在总结目前对急性心肾综合征(CRS)的认识和管理策略。
急性 CRS 的定义仍存在争议,部分原因是缺乏对肾脏盐和水处理的可靠了解,除了肾小球滤过功能受损。方案化使用袢利尿剂以确保将其作用于靶标,以及联合使用噻嗪类利尿剂、乙酰唑胺、阿米洛利或钠-葡萄糖共转运蛋白 2(SGLT2)抑制剂来阻断肾小管的节段,可以使急性 CRS 患者实现更有效的排钠,这些患者表现出利尿剂抵抗。其他策略,如使用高渗盐水调节肾脏对钠的摄取、降低腹内压或基于设备的盐和容量去除,具有很大的潜力,值得进一步研究。急性 CRS 仍然是急性心力衰竭患者发病率和死亡率的重要原因。新策略挑战了我们对其病理生理学的理解的现有观念,这可能会带来新的潜在治疗方法。